ERR2278858
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.410
- PROTEIN_SECRETION+0.380
- HYPOXIA+0.370
- MYC_TARGETS_V1+0.370
- E2F_TARGETS+0.360
- G2M_CHECKPOINT+0.330
- ANDROGEN_RESPONSE+0.310
- PANCREAS_BETA_CELLS+0.310
- UV_RESPONSE_DN+0.300
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.230
- OXIDATIVE_PHOSPHORYLATION-0.200
- INTERFERON_GAMMA_RESPONSE-0.170
- FATTY_ACID_METABOLISM-0.150
- BILE_ACID_METABOLISM-0.120
- MYOGENESIS-0.120
- XENOBIOTIC_METABOLISM-0.120
- DNA_REPAIR-0.110
- PI3K_AKT_MTOR_SIGNALING-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 247323b2-dc45-427e-bc41-c33f2fbbe77b | — | — | 0.810 |
| 2 | SJEPD032263_D1.RNA-Seq | EPN | Anaplastic EPN | 0.787 |
| 3 | SRR8518155 | — | E | 0.779 |
| 4 | BS_MKM0EEN1 | Diffuse intrinsic pontine glioma | — | 0.772 |
| 5 | SRR4195688 | — | — | 0.769 |
| 6 | SAMN03290908 | — | — | 0.768 |
| 7 | TCGA-BH-A0AV-01A-31R-A115-07 | — | E | 0.764 |
| 8 | TCGA-44-8119-01A-11R-2241-07 | — | cohortA3 | 0.762 |
| 9 | SRR4195651 | — | — | 0.759 |
| 10 | TCGA-77-7337-01A-21R-2045-07 | — | cohortSQ1 | 0.740 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.480 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.410 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| HYPOXIA | 0.370 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.310 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.270 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| COAGULATION | 0.130 | Binimetinib | — uncovered |
| COMPLEMENT | 0.130 | Inavolisib | — uncovered |